Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$341.80
+7.2%
$291.24
$170.99
$341.99
$37.46B0.21319,790 shs357,675 shs
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$38.18
-3.6%
$39.29
$21.95
$41.60
$10.78B0.11245 shs445 shs
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
$61.42
+0.7%
$58.61
$35.61
$63.72
$27.02B0.620,307 shs13,931 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$25.98
+9.2%
$25.85
$11.88
$36.91
$19.30B-1.023.07 million shs3.40 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+7.24%+11.68%+14.50%+33.59%+34,179,999,900.00%
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
-3.57%-3.81%-7.96%+6.88%+43.52%
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
+0.74%-2.34%+9.86%+14.78%+46.73%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+9.16%+9.62%-8.91%+26.18%+116.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$341.80
+7.2%
$291.24
$170.99
$341.99
$37.46B0.21319,790 shs357,675 shs
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$38.18
-3.6%
$39.29
$21.95
$41.60
$10.78B0.11245 shs445 shs
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
$61.42
+0.7%
$58.61
$35.61
$63.72
$27.02B0.620,307 shs13,931 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$25.98
+9.2%
$25.85
$11.88
$36.91
$19.30B-1.023.07 million shs3.40 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+7.24%+11.68%+14.50%+33.59%+34,179,999,900.00%
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
-3.57%-3.81%-7.96%+6.88%+43.52%
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
+0.74%-2.34%+9.86%+14.78%+46.73%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+9.16%+9.62%-8.91%+26.18%+116.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.00
Buy$330.89-3.19% Downside
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
2.00
HoldN/AN/A
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
2.00
HoldN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.65
Moderate Buy$33.7930.05% Upside

Current Analyst Ratings Breakdown

Latest ORINY, ONC, SDZNY, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$40.00
9/2/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/27/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $50.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$21.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$40.00
8/18/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$21.00
8/15/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00
8/14/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
8/12/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $34.00
8/8/2025
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$3.81B9.83N/AN/A$34.10 per share10.02
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$1.67B6.46$1.62 per share23.56$3.85 per share9.92
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
$10.36B2.61$2.67 per share22.98$18.56 per share3.31
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K27,570.35N/AN/A$0.53 per share49.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$644.79M-$1.73N/A481.41N/A-3.89%-1.22%-0.72%N/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$356.98M$1.4725.9729.37N/A22.61%38.68%22.98%11/4/2025 (Estimated)
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
$1MN/A0.0018.501.07N/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)

Latest ORINY, ONC, SDZNY, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/6/2025Q2 2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billion
7/18/2025Q2 2025
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/A$0.33N/A$0.33N/A$472.57 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$0.320.84%N/A21.77%N/A
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
$0.440.72%N/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.04
1.95
1.72
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
0.15
1.86
1.05
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
0.57
1.24
0.79
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13

Institutional Ownership

CompanyInstitutional Ownership
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/A
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
0.06%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.62%
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/A
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
11,000109.60 million102.34 millionN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
3,712282.27 millionN/ANot Optionable
Sandoz Group AG Sponsored ADR stock logo
SDZNY
Sandoz Group
23,406440.00 millionN/ANot Optionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable

Recent News About These Companies

HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
3 No-Brainer Stocks to Buy Right Now
What is HC Wainwright's Forecast for SMMT FY2026 Earnings?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$341.80 +23.07 (+7.24%)
As of 09/5/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Orion OYJ stock logo

Orion OYJ OTCMKTS:ORINY

$38.18 -1.41 (-3.57%)
As of 09/5/2025 11:03 AM Eastern

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Sandoz Group stock logo

Sandoz Group OTCMKTS:SDZNY

$61.42 +0.45 (+0.74%)
As of 09/5/2025 03:56 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$25.98 +2.18 (+9.16%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$25.93 -0.05 (-0.19%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.